| scholarly article | Q13442814 |
| P50 | author | Gene Kim | Q55153249 |
| P2093 | author name string | Gabriel Sayer | |
| Nir Uriel | |||
| James K Liao | |||
| Valluvan Jeevanandam | |||
| Corey E Tabit | |||
| Savitri E Fedson | |||
| Phetcharat Chen | |||
| Mitchell J Coplan | |||
| P2860 | cites work | Von Willebrand factor, angiodysplasia and angiogenesis | Q26852889 |
| High-resolution crystal structure of human protease-activated receptor 1 | Q27675402 | ||
| Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? | Q81250264 | ||
| Prognostic impact of angiopoietin-2 in multiple myeloma | Q88034725 | ||
| Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells | Q28203283 | ||
| Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices | Q28293775 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis | Q30541878 | ||
| Thrombin upregulates the angiopoietin-Tie2 Axis: endothelial protein C receptor occupancy prevents the thrombin mobilization of angiopoietin 2 and P-selectin from Weibel-Palade bodies | Q33940353 | ||
| Shear stress-activated Wnt-angiopoietin-2 signaling recapitulates vascular repair in zebrafish embryos. | Q34214238 | ||
| Endothelial destabilization by angiopoietin-2 via integrin β1 activation. | Q35047913 | ||
| Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus | Q35144163 | ||
| The role of angiopoietins during angiogenesis in gliomas | Q36359226 | ||
| Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus | Q36610687 | ||
| Angiopoietin-2 secretion by endothelial cell exosomes: regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways. | Q37428684 | ||
| Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation | Q37583313 | ||
| Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. | Q37956591 | ||
| Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? | Q37970070 | ||
| The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. | Q38117737 | ||
| Expression of Angiogenic Factors in Patients With Sporadic Small Bowel Angiodysplasia | Q39112499 | ||
| Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. | Q39899888 | ||
| The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture | Q40622814 | ||
| Human endothelium: endovascular biopsy and molecular analysis | Q40930454 | ||
| Angiopoietins-1 and -2 play opposing roles in endothelial sprouting of embryoid bodies in 3D culture and their receptor Tie-2 associates with the cell-cell adhesion molecule PECAM1. | Q41864287 | ||
| Thrombin activity resides on LVAD Dacron inflow and outflow grafts | Q42036187 | ||
| Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors | Q43054611 | ||
| Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: implications for antiangiogenic/antithrombotic strategies. | Q43273531 | ||
| Left ventricular assist device thrombosis: another piece of the puzzle? | Q43446499 | ||
| Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium | Q43884350 | ||
| Gastrointestinal bleeding with the HeartMate II left ventricular assist device | Q43969687 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| Comparison of hemodynamics in the ascending aorta between pulsatile and continuous flow left ventricular assist devices using computational fluid dynamics based on computed tomography images | Q45328741 | ||
| Computational fluid dynamics in patients with continuous-flow left ventricular assist device support show hemodynamic alterations in the ascending aorta | Q45894114 | ||
| Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. | Q46360793 | ||
| Gene expression of endothelial cells under pulsatile non-reversing vs. steady shear stress; comparison of nitric oxide production | Q47928164 | ||
| Increased number of circulating progenitor cells after implantation of ventricular assist devices | Q48549407 | ||
| Usefulness of a standard automated blood pressure monitor in patients with continuous-flow left ventricular assist devices. | Q50861318 | ||
| The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. | Q50933010 | ||
| Neurohormonal regulation and improvement in blood glucose control: reduction of insulin requirement in patients with a nonpulsatile ventricular assist device. | Q51322936 | ||
| Tube formation: an in vitro matrigel angiogenesis assay. | Q51757665 | ||
| Enhanced thrombin regulation during warfarin therapy in children compared to adults. | Q53350734 | ||
| Activation of endothelial and coagulation systems in left ventricular assist device recipients. | Q53370074 | ||
| Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes. | Q53426102 | ||
| IMPACT OF CARDIAC TRANSPLANTATION ON MOLECULAR PATHOLOGY OF ET-1, VEGF-C, AND MITOCHONDRIAL METABOLISM AND MORPHOLOGY IN DILATED VERSUS ISCHEMIC CARDIOMYOPATHIC PATIENTS1 | Q57496988 | ||
| Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis | Q78155515 | ||
| Formation and function of Weibel-Palade bodies | Q80240960 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| P304 | page(s) | 141-152 | |
| P577 | publication date | 2016-06-28 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding | |
| P478 | volume | 134 |
| Q64236671 | Acquired von Willebrand Syndrome in Patients With Ventricular Assist Device |
| Q104283625 | Angiopoietin-2 and hemocompatibility-related adverse events during percutaneous left ventricular assist device supports |
| Q47267322 | Anticoagulation with VADs and ECMO: walking the tightrope. |
| Q90034535 | Benchtop von Willebrand Factor Testing: Comparison of Commercially Available Ventricular Assist Devices and Evaluation of Variables for a Standardized Test Method |
| Q42369262 | Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy? |
| Q54254897 | Blood stream infection is associated with cerebrovascular accident in patients with left ventricular assist device: a systematic review and meta-analysis. |
| Q49588323 | Contemporary Perspectives in Durable Mechanical Circulatory Support: What Did We Learn in the Last 3 Years? |
| Q90726839 | Decoupling Between Diastolic Pulmonary Artery and Pulmonary Capillary Wedge Pressures Is Associated With Right Ventricular Dysfunction and Hemocompatibility-Related Adverse Events in Patients With Left Ventricular Assist Devices |
| Q90085905 | Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant |
| Q90397281 | Hemocompatibility-related Adverse Events Following HeartMate II Left Ventricular Assist Device Implantation between Japan and United States |
| Q92625470 | Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial |
| Q50087100 | Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients with a Continuous-Flow Left Ventricular Assist Device |
| Q88581991 | National Landscape of Unplanned 30-Day Readmissions in Patients With Left Ventricular Assist Device Implantation |
| Q57818806 | Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device |
| Q92076256 | Omega-3 and hemocompatibility-related adverse events |
| Q90789242 | Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events |
| Q38612227 | Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left-Ventricular Assist Devices |
| Q40052734 | Prevalence of Cerebral Microbleeds in Patients With Continuous-Flow Left Ventricular Assist Devices |
| Q42340630 | Stop the LVAD bleeding |
| Q47124541 | Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices |
Search more.